• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    method and apparatus for encapsulating a rigid insert in a contact lens to correct vision in patients with astigmatism. the present invention, as described above and further defined by the claims, provides methods for forming an ophthalmic lens that encapsulates a rigid insert, the rigid insert being adjustable to correct specific astigmatism characteristics of an eye and apparatus to implement such methods, as well as ophthalmic lenses formed with rigid inserts.
    公开号:BR102014006311B1
    申请号:R102014006311-0
    申请日:2014-03-17
    公开日:2021-08-03
    发明作者:Randall B. Pugh；Frederick A. Flitsch；Daniel B. Otts；Sharika Snook；James Daniel Riall；Stephen R. Beaton；Marina Archer；Michael D. Ferran；Camille Higham
    申请人:Johnson & Johnson Vision Care, Inc；
    IPC主号:
    专利说明:

    FIELD OF USE
    [0001] This invention describes methods, apparatus and devices related to the encapsulation aspects related to ophthalmic devices and, more specifically, in some embodiments, the sealing and encapsulation aspects in the manufacture of a contact lens for astigmatism. BACKGROUND
    [0002] Traditionally, an ophthalmic device, such as a contact lens or an intraocular lens, included a biocompatible device with a corrective, cosmetic or therapeutic quality. A contact lens, for example, can provide one or more vision correction, cosmetic optimization, and therapeutic effects functionality. The physical characteristics of the ophthalmic lens provide each function. A design incorporating a refractive quality into an ophthalmic lens can provide a vision corrective function. A pigment incorporated into the ophthalmic lens can provide a cosmetic optimization. An active agent incorporated into an ophthalmic lens can provide therapeutic functionality.
    [0003] Astigmatism is a common optical defect that is often the result of irregular or toric curvature of the cornea or lens of the eye. As a result, correcting vision in patients with astigmatism requires a more complex solution than the typical contact lens. More recently, it is therefore desirable to have additional methods and apparatus conducive to the formation of ophthalmic lenses that can correct vision in patients with astigmatism. Recently, rigid inserts have been included in ophthalmic lenses, where the rigid insert can add functionality to the ophthalmic lens. Innovative methods, devices and apparatus related to sealing and encapsulating a rigid insert within an optical lens are therefore important. SUMMARY
    [0004] Consequently, the present invention includes innovations related to a method for forming an ophthalmic lens with a rigid insert. In some embodiments, the front of the bend mold can be pre-dosed with a mixture of reactive monomers and the rigid insert can be positioned in the mixture of reactive monomer. The reactive monomer mixture can be precured to hold the insert rigidly close to the face curve mold, with the precuring forming a face curve assembly. In some embodiments, the front curve assembly process can be performed by an automated device.
    [0005] The front curve set can be post-dosed with a mixture of reactive monomers, with pre-dosing and post-dosing encapsulating the rigid insert. The back of the curve mold can be positioned close to the front curve set, with the placement forming a front curve and back curve set. In some embodiments, the reactive monomer mixture can be precured to securely hold the back curved mold close to the front curve assembly.
    [0006] The mixture of reactive monomers can be cured to form the ophthalmic lens. The front curve and posterior curve assembly can then be removed from the mold and the ophthalmic lens removed. The ophthalmic lens can then be hydrated, for example, by immersing the ophthalmic lens in a solution comprising approximately 45% sodium borate for at least one hour at a temperature around 50°C. In some embodiments, the polymerized reactive monomer mixture can comprise a hydrogel, such as, for example, a silicone hydrogel.
    [0007] In some embodiments, the rigid insert may comprise an adhesion promoting layer. The rigid insert, reactive monomer mixture, front curve mold and after curve mold can be degassed prior to use in the process where degassing removes gases that can create defects in the lens. In some embodiments, a plurality of ophthalmic lenses with rigid inserts can be formed simultaneously on a pallet.
    [0008] The rigid insert in some modalities, may be able to correct the astigmatic vision. In such modalities, the rigid insert can comprise a thermoformed material. A stabilization feature can be added to the reactive monomer mix, the stabilization feature being able to orient the ophthalmic lens in an eye. The stabilization feature can be aligned with the rigid insert, where the alignment allows correction of astigmatic vision when the ophthalmic lens is oriented in the eye. In some embodiments, the rigid insert may include a stabilization feature, such as by thermoforming processes. In other embodiments, the stabilizing feature may be an injectable material that comprises a different expandable index than the reactive monomer mixture.
    [0009] The stabilization feature can change the surface of the front curve of the ophthalmic lens or can add mass to the ophthalmic lens, where the mass is sufficient to orient the ophthalmic lens in the eye. The stabilization feature may comprise a visual guidance indicator, where the visual guidance comprises visible coloring or marking. DESCRIPTION OF DRAWINGS
    [00010] Figure 1 illustrates an exemplary modality of an ophthalmic lens with a fully encapsulated rigid insert, in which the ophthalmic lens can correct vision in patients with astigmatism.
    [00011] Figure 2 illustrates an exemplary alternative Figure 1 of the components of the mold assembly apparatus that may be useful in implementing some embodiments of the present invention.
    [00012] Figure 3 illustrates components of the exemplary mold assembly apparatus that may be useful in implementing some embodiments of the present invention.
    [00013] Figure 4 illustrates steps of the method to form a contact lens with an encapsulated rigid insert according to some embodiments of the present invention.
    [00014] Figure 5 illustrates an example of the components of an apparatus to position the rigid insert in an ophthalmic lens mold part. DETAILED DESCRIPTION
    [00015] The present invention includes methods and apparatus for fabricating an ophthalmic lens with a rigid insert, wherein the rigid insert corrects vision in patients with astigmatism. Furthermore, the present invention includes the resulting ophthalmic lens with the rigid insert. In general, in accordance with some embodiments of the present invention, the rigid insert can be integrated into an ophthalmic lens by automation, which positions a rigid insert in a desired location relative to a mold part used to manufacture the ophthalmic lens.
    [00016] Currently, ophthalmic lenses exist to correct astigmatism. For example, rigid gas permeable lenses can be placed over the cornea and a layer of tear fluid will form between the lens and the eye. The rigid gas permeable lens essentially acts like the new cornea, which can be designed to mimic the curvature of a non-astigmatic eye. This technique is considered masking. However, the typical rigid gas permeable lens is uncomfortable and expensive.
    [00017] Soft contact lenses provide a more comfortable and less expensive alternative. Unlike an RGP (rigid gas permeable lens), a tear fluid layer may not form between the eye and the lens; then, a soft contact lens can be adapted to mirror the eye's astigmatic features. The lens can contain varying energies and angles of refraction to correct each portion of the eye. However, because the lens is soft, the lens naturally conforms, to some extent, to the shape of the eye. This reduces the effectiveness of the lens and users often complain of fogging or double vision.
    [00018] Problems with comfort and effectiveness of any solution are exacerbated in patients with severe astigmatism. Consequently, the present invention provides an innovative alternative to correct vision in patients with astigmatism. An ophthalmic lens that can include a rigid insert is described, and more specifically, where an encapsulated rigid insert can provide correction for astigmatism.
    [00019] In the next sections, detailed descriptions of embodiments of the invention will be given. The description of both the preferred and alternative embodiments are exemplary embodiments only, and it should be understood by those skilled in the art that variations, modifications, and alterations may be apparent. Therefore, it should be understood that said exemplary embodiments do not limit the scope of the invention on which they are based. GLOSSARY
    [00020] In this description and in the claims related to the presented invention, several terms can be used, to which the following definitions will apply:
    [00021] Adhesion Promotion: as used herein, refers to a process that increases adhesive tendencies between two surfaces, such as between a rigid insert and an encapsulant.
    [00022] Posterior curve piece or posterior insert piece: as used herein, refers to a solid element of a multi-piece rigid insert that, when mounted on said insert, will occupy a location beside the ophthalmic lens that is on the back. In an ophthalmic device, such a part would be located on the side of the insert that would be closest to the surface of the user's eye. In some embodiments, the posterior curve piece may contain and include a region in the center of the ophthalmic device through which light may proceed into the wearer's eye. This region can be called an optical zone. In other embodiments, the part may take an annular shape where it does not contain or include some or all of the regions in an optical zone. In some embodiments of an ophthalmic insert, there may be multiple curved back pieces, one of which may include an optical zone, while others may be annulars or portions of a ring.
    [00023] Component: as used herein, refers to a device capable of extracting electrical current from an energy source to effect one or more of a logical or physical state change.
    [00024] Encapsulated: as used here, refers to creating a barrier to separate an entity, such as a media insert, from an environment adjacent to the entity.
    [00025] Encapsulant: as used herein, refers to a layer formed surrounding an entity, such as a media insert, that creates a barrier to separate the entity from an environment adjacent to the entity. For example, encapsulants can be comprised of silicone hydrogels such as Etafilcon, Galifilcon, Narafilcon and Senofilcon or other hydrogel contact lens material. In some embodiments, an encapsulant may be semipermeable to contain specified substances within the entity and preventing specified substances, such as water, from entering the entity.
    [00026] Energized: as used herein, refers to the state of being able to supply electrical current or having electrical energy stored in it.
    [00027] Energy: as used herein, refers to the ability of a physical system to perform work. Many uses comprised in the present invention can be related to said ability to perform electrical actions in carrying out the work.
    [00028] Power Source: as used herein, refers to a device capable of providing Energy or placing a biomedical device into an Energized state.
    [00029] Energy Harvesters: as used herein, refers to the device capable of extracting energy from the environment and converting it into electrical energy.
    [00030] Front Curve Part or Front Insert Part: as used herein, refers to a solid element of a multi-part rigid insert which, when mounted on said insert, will occupy a location beside the ophthalmic lens that is ahead. In an ophthalmic device, such a part would be located on the side of the insert that would be farthest from the surface of the user's eye. In some embodiments, the part may contain and include a region in the center of an ophthalmic device through which light may proceed into the wearer's eye. This region can be called an optical zone. In other embodiments, the part may take an annular shape where it does not contain or include some or all of the regions in an optical zone. In some embodiments of an ophthalmic insert, there may be multiple front curve pieces, one of which may include an optical zone, while others may be annulars or portions of a ring.
    [00031] Lens Forming Mixture or Reactive Mixture or Mixture of Reactive Monomers (MRM): As used herein, refers to a monomer or prepolymer material that can be cured and crosslinked to form an ophthalmic lens. Various embodiments can include mixtures of reactive monomers with one or more additives such as, for example, UV blockers, shades, photoinitiators or catalysts, and other additives useful in ophthalmic lenses such as contact lenses or intraocular lenses.
    [00032] Lens Forming Surface: As used herein, refers to a surface that is used to mold an ophthalmic lens. In some embodiments, any such surface may have an optical quality surface finish, which indicates that it is sufficiently smooth and formed such that an ophthalmic lens surface is manufactured by polymerizing a lens-forming mixture in contact with the mold surface. it is optically acceptable. Additionally, in some embodiments, the lens forming surface may have a geometry that is necessary to impart to the ophthalmic lens surface the desired optical characteristics, including without limitation, spherical, aspherical and cylindrical power, wavefront aberration correction, corneal topography correction or combinations thereof.
    [00033] Lithium Ion Cell: as used herein, refers to an electrochemical cell in which lithium ions move through cells to generate electrical energy. This electrochemical cell, typically called a battery, can be re-energized or recharged in its typical form.
    [00034] Media Insert Element: as used herein, refers to an encapsulated insert that will be included in an energized ophthalmic device. Power and circuit elements can be built into the media insert. The media insert defines the primary purpose of the energized ophthalmic device. For example, in modes where the energized ophthalmic device allows the user to adjust optical power, the media insert may include energizing elements that control a portion of liquid meniscus in the optical zone. Alternatively, a media insert can be annular so that the optical zone is devoid of material. In such embodiments, the energized lens function may not be of optical quality but may be, for example, monitoring glucose or administering medication.
    [00035] Mold: as used herein, refers to a rigid or semi-rigid object that can be used to form ophthalmic lenses from uncured formulations. Some preferred molds include two mold parts forming a front curve mold and a back curve mold.
    [00036] Ophthalmic lens or ophthalmic device or lens: as used herein, refers to any device that resides in or on the eye. The device may provide optical correction, it may be cosmetic, or it may provide some functionality not related to optical quality. For example, the term lens may refer to a contact lens, intraocular lens, overlay lens, eye insert, optical insert, or other similar device, through which vision is corrected or modified, or through which the physiology of the eye is cosmetically improved (eg iris color) without impairing vision. Alternatively, a lens can refer to a device that can be positioned in the eye with a function other than vision correction, such as monitoring a constituent of the tear fluid or a means of administering an active agent. In some embodiments, preferred lenses of the invention can be soft contact lenses that are made of silicone elastomers or hydrogels, which can include, for example, silicone hydrogels and fluorine hydrogels.
    [00037] Optical zone: as used herein, refers to an area of an ophthalmic lens through which a wearer of the ophthalmic lens sees.
    [00038] Power: as used herein, refers to work performed or energy transferred per unit of time.
    [00039] Pre-cure: as used here, refers to a process that partially cures a mixture. In some modalities, a pre-cure process may comprise a shortened period of the full healing process. Alternatively, the precuring process can comprise a single process, for example exposing the mixture to different temperatures and wavelengths which can be used to fully cure the material.
    [00040] Pre-Batch: As used herein, refers to the deposition of initial material in an amount that is less than the total amount that may be required to complete the process. For example, a pre-dose may include a quarter of the required substance.
    [00041] Post-dosing: As used herein, refers to a deposition of material in the amount remaining, after pre-dosing, which may be necessary for the completion of the process. For example, where the pre-dose includes one-quarter of the required substance, a post-dose may provide the remaining three-quarters of the substance.
    [00042] Rechargeable or re-energizable: as used here, refers to a capability of restoring to a state with greater capability to do work. Many uses within this invention may relate to the ability to be restored to a restored state with the ability to flow electrical current at a certain rate for a certain period of time.
    [00043] Reload or re-energize: as used here, refers to an act of restoring to a state with greater capacity to do the job. Many uses within this invention can be related to restoring a device to a state with the ability to flow electrical current at a certain rate for a reestablished period of time.
    [00044] Released from a Mold: as used herein, refers to an act where an ophthalmic lens is either completely detached from the mold or is just loosely attached so that it can be removed with gentle agitation or pushed out with a cotton swab.
    [00045] Hard Insert: as used here, refers to an insert that maintains a predefined topography. When included with a contact lens, the rigid insert can contribute to lens functionality. For example, varying the topography of or densities within the rigid insert can define zones, which can correct vision in users with astigmatism.
    [00046] Stabilization Feature: as used herein, refers to a physical feature that stabilizes an ophthalmic device to a specific orientation in the eye when the ophthalmic device is positioned in the eye. In some modalities, the stabilization feature can add enough mass to stabilize the ophthalmic device. In some modalities, the stabilization feature can change the surface of the front curve, where the eyelid can catch the stabilization feature and the user can re-orient the lens when blinking. Such modalities can be improved by including stabilization features that can add mass. In some exemplary embodiments, stabilization features can be a separate material from the biocompatible encapsulation material, can be an insert formed separately from the molding process, or can be included in the rigid insert or media insert.
    [00047] Integrated Component Grouping Devices (SIC Devices): As used herein, refers to the product of packaging technologies that can group thin layers of substrates, which may contain electrical and electromechanical devices, into integrated devices operational by means of stacking at least a portion of each layer on top of each other. Layers can comprise component devices of various types, materials, shapes and sizes. Furthermore, layers can be made of various device production technologies to fit and take on various contours. EXPANSION INDEX: OPHTHALMIC LENSES
    [00048] Proceeding to Figure 1, an exemplary embodiment of ophthalmic lens 100 with a rigid insert 110, wherein the rigid insert 110 includes physical attributes that correct vision for patients with astigmatism, is illustrated. In some embodiments, a rigid insert 110 can mirror the astigmatic features of the eye. For example, rigid insert 110 can include a first region 111 with a first power and refraction angle and a second zone 112 with a second power and refractive angle. In some embodiments, the first zone 111 may not be located exactly in the center of the eye and the second zone 112 may not be radially symmetric.
    [00049] In such modalities, stabilization features 120 may be needed to properly orient the ophthalmic lens 100 in the eye. Stabilizing features 120 may comprise a material that is different from the encapsulation reactive monomer blend. In some embodiments, material for stabilizing features 120 may be positioned in a front curve mold piece prior to positioning the rigid insert 110. Alternatively, the material can be injected into the ophthalmic lens 100 after the rigid insert 110 has been positioned. between the front curve mold part and the rear curve mold part.
    [00050] As shown in cross section, the stabilization feature 120 can orient the ophthalmic lens 100 in the eye by adding enough mass to anchor the ophthalmic lens 100 to prevent rotation in the eye. In some alternative embodiments, the stabilization feature 110 may comprise a material with an expandable index different from the encapsulation MRM. In such embodiments, the stabilization feature 110 may expand during the process of forming the ophthalmic lens 100, wherein the swelling allows the stabilization feature 110 to change the topography of the front surface of the ophthalmic lens 100. When positioned on the eye, the eyelid It can hold the stabilization feature 110, and the user can orient the lens again by blinking. To facilitate positioning in the eye, the stabilization feature 110 can contain a tint, in which the user can see how the ophthalmic lens 100 can orient itself in the eye prior to positioning.
    [00051] In some embodiments a rigid insert can be formed by thermoforming an aligned sheet and held in a three-dimensional shape that can replicate the surface of a thermoforming mold part. The resulting piece can be cut from the thin sheet of material. By placing the rigid insert within a cavity defined by front curve and rear curve mold pieces and surrounding the insert with the reactive monomer mixture an ophthalmic lens can be formed. During the process of cutting the pieces of thermoforming material, alignment features can be cut inside the insert fragment such as notches, grooves or flats for example. These features can be used to align the insert part or ophthalmic insert devices formed in subsequent processing.
    [00052] Proceeding to Figure 2, an alternative embodiment of an ophthalmic lens 200 with a rigid insert 210, wherein the rigid insert 210 includes physical attributes to correct vision in patients with astigmatism, as illustrated. In patients with severe astigmatism, the rigid insert 210 can include a complex configuration of zones 211 and 213, where each zone 211 and 213 corrects vision for a specific portion of the eye. The rigid insert 210 can be fully encapsulated in the ophthalmic lens 200 and may not have direct eye contact. Consequently, in some embodiments, rigid insert 210 can comprise a variety of material, where the materials may not be biocompatible. For example, a first zone 211 may include a different material than a second zone 212 or third zone 213. The properties of each material may increase the effectiveness of vision correction for each zone 211 and 213 or only the properties may be sufficient to correct the astigmatic features. Properties can include, for example, density or refractive index.
    [00053] In some embodiments, the rigid insert 210 can be formed through the thermoforming process. For example, in embodiments where each zone 211 and 213 comprises a unique material, a thin sheet may be regionally coated with each material. The thin sheet or a rigid insert cut from a thin sheet can be thermoformed to include a three-dimensional surface, where the topography of the three-dimensional surface of the rigid insert contributes to the correction of the astigmatic features of the eye. In some embodiments, the three-dimensional surface may be sufficient to create the necessary zones 211 to 213.
    [00054] In some 200 ophthalmic lens embodiments, which include 210 rigid inserts with multiple zones, and particularly where the 210 rigid insert includes complex variation, 220 stabilization features may be included with the 210 rigid insert. This can allow for precise alignment between the stabilizing features 220 and the rigid insert 210. In some specific embodiments where the rigid insert 210 can be thermoformed, the rigid insert can be cut from the thin sheet to include the stabilizing features 220, as shown in cross section where the stabilization feature 220 extends from the rigid insert 220.
    [00055] Similar to Figure 1, the stabilization feature 220 can change the topography of the front surface so that the user can orient the ophthalmic lens 200 by flashing or, in some modalities, the stabilization feature 220 can add enough mass to guide the 200 ophthalmic lens in the eye. Some other modalities may include a combination of altered frontal surface mass and topography. Stabilization feature 220 may include additional features that can assist the user in properly orienting the ophthalmic lens 200. For example, the stabilization feature 220 may include an inscription or tinting to indicate to the user how the ophthalmic lens 200 may be positioned on the eye .
    [00056] In some embodiments, other passive elements may be included with the rigid insert 210. In some embodiments, the rigid insert 210 may include bias elements that can reduce glare, which can increase vision acuity. In some embodiments, rigid insert 210 can include a printed pattern that can add cosmetic functionality, including a concealment of zones 211 and 213 on rigid insert 210. In some embodiments, rigid insert 210 can include an active agent that can dissolve when the 200 ophthalmic lens is positioned in the eye. Modalities in which the active agent is a drug may be particularly significant where astigmatism is caused by damage to the eye.
    [00057] Proceeding to Figure 3, exemplary processing steps to form an ophthalmic lens 309 with a 304 rigid insert, wherein the 304 rigid insert is encapsulated and may be able to correct astigmatic vision, are illustrated. Exemplary materials and curing specifications are included in Table 1, but other materials and polymerization techniques may be apparent and are within the scope of the technique of the invention described. At 310, a front curve mold 301 can be pre-metered with reactive monomer mixture 303. In some embodiments, the stabilization features 302 can be deposited on the front curve mold 301 or pre-metered MRM 303.
    [00058] At 320, a rigid insert 304 can be positioned close to the front curve mold 304 and in contact with the pre-metered MRM, in which the positioning forms front curve sets 301 and 304. In mode where the stabilization feature 302 is separate from rigid insert 304, rigid insert 304 can be aligned with stabilization feature 302 and positioned to allow proper orientation of ophthalmic lens 309 when ophthalmic lens 309 is positioned in the eye.
    [00059] At 330, the front curve sets 301 and 304 can be post-dosed with 305 reactive monomer mixture, with the pre-dosing amount 303 and the post-dosing amount 305 can fully encapsulate the 304 rigid insert and suitably forming an ophthalmic lens 308. At 340, a trailing curve mold 306 can be positioned proximate to the front curve mold 301, wherein the front curve mold 301 and the posterior curve mold 306 can form a cavity forming cavity. 308 lens. The 308 lens forming cavity can combine the 305 post-dosed MRM and the 303 pre-dosed MRM, which can allow the 307 MRM to fully encapsulate the 304 rigid insert.
    [00060] In some embodiments, the MRM 307 can adhere to or at least partially encapsulate the stabilization features 303. The front curve assembly and the posterior curve assembly 301 and 307 can be polymerized, for example, through a process of cures to form ophthalmic lens 309. At 350, ophthalmic lens 309 can be removed from molding apparatus 301 and 306. Table 1 - Partial listing of exemplary sealing materials, encapsulating materials, and coating materials

    [00061] Elements can be formed of materials that may or may not be stable in environments that ophthalmic devices occupy, including, for example, the tear fluid on an ocular surface that comes in contact with the element. Use may include forming encapsulating layers of coatings, including, for example, a parylene family including, but not limited to, elements of the C, N, and D parylene family. In some embodiments, the encapsulating coating may occur before or after the application of other layers of adhesive or sealant. METHODS AND MATERIALS FOR INSERT-BASED OPHTHALMIC LENSES
    [00062] Referring again to Figure 3, exemplary process steps for forming an ophthalmic lens 309 with a 304 rigid insert, wherein the 304 rigid insert is encapsulated and may be able to correct astigmatic vision, are illustrated. As used herein, the apparatus of molds 301 and 306 can include a plastic formed to form a lens-forming cavity 308, into which the lens-forming mixture 307 can be dispensed and, upon reaction or curing of the lens-forming mixture. 307, an ophthalmic lens 309 of a desired shape is produced. The combination of mold parts 301 and 306 is preferably temporary, whereby upon formation of the ophthalmic lens 309, the mold parts 301 and 306 can be separated for 350 removal of ophthalmic lenses 309.
    [00063] At least a part of the molds 301 and 306 may have at least a portion of its surface in contact with the lens-forming mixture 307, so that upon reaction or curing of the lens-forming mixture 307 the surface provides a desired shape and conformance to the portion of the ophthalmic lens with which it is in contact. The same is true for at least another part of templates 301 and 306.
    [00064] Thus, for example, in an exemplary modality, the apparatus of molds 301 and 306 is formed of two parts 301 and 306, a female concave part (front curve mold) 301 and a male convex part (mold curve) 306 with a cavity 308 formed between them. The portion of the concave surface that makes contact with the lens-forming mixture 307 has the curvature of the front curve of an ophthalmic lens 309.
    [00065] Said portion is sufficiently smooth and formed so that the surface of an ophthalmic lens 309, formed by polymerization of lens-forming mixture 307 that is in contact with the concave surface, is optically acceptable. In some embodiments, the front bend mold 301 may also have an integral annular flange to and surrounding a circumferential circular end that extends from the front bend mold 301 in a plane normal to the axis and also extends from the flange ( not shown).
    [00066] A lens forming surface may include a surface with an optical quality surface finish, indicating that it is smooth enough and formed so that an ophthalmic lens surface manufactured by polymerizing a lens forming mixture 308 in contact with the mold surface is optically acceptable. Additionally, in some embodiments, the lens-forming surfaces of mold parts 301 and 306 may have a geometry that is necessary to impart to the ophthalmic lens surface the desired optical characteristics, including, but not limited to, spherical, aspherical power. and cylindrical; correction of wavefront aberration; corneal topography correction; and combinations thereof. One of ordinary skill in the art will recognize that features other than those discussed may also be included within the scope of the invention.
    [00067] Some additional embodiments include a 304 rigid insert that can be fully encapsulated within a hydrogel matrix. A rigid insert 304 can be manufactured, for example, using microinjection molding technology. Embodiments may include, for example, a poly(4-methyl penta-1-ene) copolymer resin having a diameter of between about 6 mm to 10 mm and a front surface radius of between about 6 mm and 10 mm. and a rear surface radius of between about 6mm and 10mm and a center thickness of between about 0.050mm and 0.5mm. Some exemplary embodiments include an insert having a diameter of about 8.9 mm, a radius of the anterior surface of about 7.9 mm, a radius of the posterior surface of about 7.8 mm, a center thickness of about 0.100 mm and an edge profile with a radius of about 0.050. An exemplary microforming machine might include the Microsystem 50 4536-kg (five tons) system offered by Battenfield Inc. Some or all of the sealing features, including, but not limited to, grooves, slits, flaps, and edges can be formed during the molding process or formed thereafter by subsequent processing of the result of the molding process.
    [00068] The rigid insert 304 can be positioned in mold parts 301 and 306 to form an ophthalmic lens 308. The material of mold parts 301 and 306 can include, for example, a polyolefin of one or more of the following: polypropylene, polystyrene, polyethylene, polymethyl methacrylate and modified polyolefins. Other molds can include a ceramic or metallic material.
    [00069] Other mold materials can be combined with one or more additives to form the ophthalmic lens mold including, for example Zieglar-Natta propylene resins (sometimes called znPP); a clear molding clarified copolymer as per FDA regulation 21 CFR (c) 3.2; a random copolymer (znPP) with the ethylene group.
    [00070] Still further, in some embodiments, the molds of the invention may contain polymers such as polypropylene, polyethylene, polystyrene, polymethyl methacrylate, modified polyolefins containing an alicyclic portion in the main chain and cyclic polyolefins. This mixture can be used on one or both halves of the mold. Preferably, this mixture is used in the rear curve, and the front curve consists of alicyclic copolymers.
    [00071] In some preferred methods for manufacturing molds 300 according to the present invention, injection molding is used according to known techniques. Modalities may also include molds manufactured by other techniques including, for example, turning, diamond turning or laser cutting.
    [00072] Typically, ophthalmic lenses are formed on at least one surface of both mold parts 301 and 302. However, in some embodiments, one surface of an ophthalmic lens may be formed from one mold part 301 and 302 and another surface of an ophthalmic lens can be formed, for example, using a turning method.
    [00073] In some embodiments, a type of ophthalmic lens may include an ophthalmic lens that includes a silicone-containing component. A silicone-containing component is one that contains at least one [-Si-O-] unit in a monomer, macromer or prepolymer. Preferably, the total fixed silicone and attached oxygen are present in the silicone-containing component in an amount greater than about 20 percent by weight, and more preferably greater than about 30 percent by weight of the total molecular weight of the silicone-containing component . Useful silicone-containing components preferably comprise polymerizable functional groups such as acrylate, methacrylate, acrylamide, methacrylamide, vinyl, N-vinyl lactam, N-vinylamide, and styryl functional groups.
    [00074] In some embodiments, the edge of the ophthalmic lens, also called an insert encapsulation layer, which surrounds the insert, may be comprised of standard hydrogel ophthalmic lens formulations. Exemplary materials with characteristics that can provide an acceptable match to a number of insert materials may include, but are not limited to, the deNarafilcon family (including Narafilcon A and Narafilcon B), and the Etafilcon family (including Etafilcon A). A more technically inclusive discussion follows the nature of the materials consistent with the technique of the present invention. One of ordinary skill in the art may recognize that material other than those discussed may also form an acceptable shell or partial shell of the sealed and encapsulated inserts and should be considered consistent and included within the scope of the claims.
    [00075] Components containing compounds of Formula I

    [00076] Wherein R1 is independently selected from monovalent reactive groups, monovalent alkyl groups, or monovalent aryl groups, any of which additionally comprise functionality selected from hydroxy, amino, oxa, carboxy, alkyl carboxy, alkoxy, starch, carbamate, carbonate , halogen or combinations thereof; monovalent siloxane chains comprising 1-100 Si-O repeating units which may further comprise alkyl, hydroxy, amino, oxa, carboxy, alkyl carboxy, alkoxy, starch, carbamate, halogen functionality or combinations thereof;
    [00077] where b is from 0 to 500, in cases where it is understood that when b is different from 0, b is a distribution that has a mode equal to the specified value;
    [00078] where at least one R1 comprises a monovalent reactive group and, in some embodiments, between one and three R1 comprise monovalent reactive groups.
    [00079] as used herein, monovalent reactive groups are groups that can undergo free radical polymerization and/or cationic polymerization. Non-limiting examples of free radical reactive groups include (methyl)acrylates, styryls, vinyls, vinyl ethers, C1-6alkyl(meth)acrylates, (meth)acrylamides, C1-6alkyl(meth)acrylamides, N-vinyllactams, N- vinylamides, C2-12alkenyls, C2-12alkenylphenyls, C2-12alkenylnaphthyls, C2-6alkenylphenylC1-6alkyls, O-vinylcarbamates, and O-vinylcarbonates. Non-limiting examples of cationic reactive groups include vinyl ethers or epoxide groups and mixtures thereof. In one embodiment, the free radical reactive groups comprise (meth)acrylate, acryloxy, (meth)acrylamide, and mixtures thereof.
    [00080] Suitable alkyl and aryl groups include monovalent C1-16 alkyl groups, C6-14 aryl groups such as those substituted or unsubstituted by methyl, ethyl, propyl, butyl, 2-hydroxypropyl, propoxypropyl, polyethylene oxypropyl, combinations of same and similar.
    [00081] In an embodiment b is 0, one R1 is a reactive monovalent group, and at least three R1 are selected from monovalent alkyl groups having 1 to 16 carbon atoms or, in another embodiment, from monovalent alkyl groups having 1 to 6 carbon atoms. Some non-limiting examples of silicone components of this embodiment include 2-methyl-2-hydroxy-3-[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propoxy]propyl ester ( "SiGMA"), 2-hydroxy-3-methacryloxypropyloxypropyl-tris(trimethylsiloxy)silane, 3-methacryloxypropyltris(trimethylsiloxy)silane ("TRIS"), 3-methacryloxypropylbis(trimethylsiloxy)methyl silane, and 3-methacryloxypropylpentamethyl disiloxane.
    [00082] In another mode, b is 2 to 20, 3 to 15 or, in some modes, 3 to 10; at least one terminal R1 comprises a monovalent reactive group and the remaining R1 are selected from monovalent alkyl groups having 1 to 16 carbon atoms or, in another embodiment, from monovalent alkyl groups having 1 to 6 carbon atoms. b is 3 to 15, one terminal R1 comprises a monovalent reactive group, the other terminal R1 comprises an alkyl group having 1 to 6 carbon atoms, and the remaining R1 comprises a monovalent alkyl group having 1 to 3 carbon atoms. Non-limiting examples of silicone components of this embodiment include ether-terminated polydimethylsiloxane (mono-(2-hydroxy-3-methacryloxypropyl)-propyl (400-1000 MW)) ("OH-mPDMS"), and mono-n-terminated polydimethylsiloxanes -butyl monomethacryloxypropyl (800-1000 MW) (mPDMS)
    [00083] In another embodiment, b is 5 to 400 or 10 to 300, both terminal R1 comprise monovalent reactive groups, and the remaining R1 are independently selected from monovalent alkyl groups having 1 to 18 carbon atoms, which may have ether bonds between carbon atoms and may additionally comprise halogen.
    [00084] In one embodiment, where a silicone hydrogel ophthalmic lens is desired, the ophthalmic lens of the present invention will be made of a reactive mixture comprising at least approximately 20 percent and preferably between approximately 20 to 70 percent by weight of components containing silicone based on the total weight of the reactive monomeric components from which the polymer is made.
    [00085] In another embodiment, one to four R1 comprise a vinyl carbonate or carbamate of Formula II

    [00086] where Y denotes O-, S- or NH-; and R denotes hydrogen or methyl d is 1, 2, 3, or 4; and q is 0 or 1.
    [00087] Silicone-containing vinyl carbonate or vinyl carbamate monomers specifically include 1,3-bis[4-(vinyloxycarbonyloxy)but-1-yl]tetramethyl-disiloxane; 3-(vinyloxycarbonylthio)propyl-[tris(trimethylsiloxy)silane]; 3-[tris(trimethylsiloxy)silyl]propylallyl carbamate; 3-[tris(trimethylsiloxy)silyl]propylvinyl carbamate; trimethylsilylethylvinyl carbonate; trimethylsilylmethylvinyl carbonate, and

    [00088] Where biomedical devices with modulus below approximately 200 are desired, only one R1 should comprise a monovalent reactive group and no more than two of the R1 groups will comprise monovalent siloxane groups.
    [00089] Another class of silicone-containing components includes polyurethane macromers with the following formulas:

    [00090] wherein D denotes an alkyl diradical, an alkylcycloalkyl diradical, a cycloalkyl diradical, an aryl diradical, or an alkylaryl diradical having 6 to 30 carbon atoms;
    [00091] where G denotes an alkyl diradical, a cycloalkyl diradical, an alkylcycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 1 to 40 carbon atoms and which may contain ether, thio or amine bonds in the main chain;• denotes a urethane or ureido bond;
    [00092] a is at least 1; and
    [00093] A denotes a divalent polymeric radical of the formula:

    [00094] wherein R11 independently denotes an alkyl or fluorine-substituted alkyl group having 1 to 10 carbon atoms, which may contain ether bonds between the carbon atoms; y is at least 1; ep gives a portion weight from 400 to 10,000; each of E and E1 independently denotes a polymerizable unsaturated organic radical represented by Formula VIII

    [00095] where R12 is hydrogen or methyl R13 is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a radical — CO—Y—R15 where Y is —O—, Y—S— or —NH —; R14 is a divalent radical having 1 to 12 carbon atoms; X denotes —CO— or — OCO—; Z denotes —O— or —NH—; Ar denotes an aromatic radical having 6 to 30 carbon atoms; w is 0 to 6; x is 0 or 1; y is 0 or 1; and z is 0 or 1.
    [00096] A preferred silicone-containing component is a polyurethane macromer represented by Formula IX (the complete structure should be understood by joining the corresponding asterisk regions, * to *, ** to **)

    [00097] where R16 is a di-radical of a di-isocyanate after removal of the isocyanate group, as the di-radical of isophorone di-isocyanate. Another suitable silicone-containing macrometer is a compound of Formula X (where x + y is a number in the range 10 to 30) formed by the reaction of fluorether, hydroxy-terminated polydimethylsiloxane, isophorone diisocyanate, and isocyanatoethylmethacrylate.
    [00098] Formula X (the total structure can be understood by joining the regions of the corresponding asterisks, * to *)

    [00099] Other silicone-containing components suitable for use in this invention include macromers containing polysiloxane, polyalkylene ether groups, diisocyanate, polyfluorinated hydrocarbon, polyfluorinated ether and polysaccharide; polysiloxanes with a fluorinated polar graft or side group that have a hydrogen atom bonded to a terminally substituted difluorine carbon atom; hydrophilic siloxanyl methacrylates containing ether and siloxanyl linkages and crosslinkable monomers containing polyether and polysiloxanyl groups. Any of the aforementioned polysiloxanes can also be used as the silicone-containing component in this invention. LAW SUIT
    [000100] The following methodological steps are provided as examples of processes that can be implemented according to some aspects of the present invention. It should be understood that the order in which the methodological steps are presented is not intended to be limiting and other orders may be used to implement the invention. Furthermore, not all steps are necessary to implement the present invention and additional steps may be included in various embodiments of the present invention. It may be obvious to the person skilled in the art that additional modalities may be practical, and such methods are well within the scope of the claims.
    [000101] Referring now to Figure 4, a flowchart illustrates exemplary steps that can be used to implement the present invention. Throughout the process, plastic-containing components can be degassed prior to implementing a step using the plastic-containing component. Degassing can remove gas such as oxygen or dissolved gases that can inhibit polymerization or create other lens defects, including gross defects such as holes or puddles.
    [000102] At 405, a rigid insert capable of correcting specific astigmatic features of an eye can be formed. The rigid insert can include multiple zones, each zone correcting vision for a specific portion of the astigmatic eye. Prior to inclusion of the molding process, the rigid insert can be plasma cleaned.
    [000103] At 410, the rigid insert can be treated to increase the rigid insert adhesive tendencies of the encapsulation reactive monomer mixture. In some modalities, the formation of the rigid insert may include treatment to promote adherence. Adhesive trends between the MRM and the rigid insert can be promoted through a vapor deposition, in which the rigid insert is exposed to an adhesion promoting chemical while stored in a vacuum chamber.
    [000104] In 412, the front curve mold can be positioned concave side up on a clamping plate including, for example, a pallet. At 415, the front curve mold can be pre-dosed with a mixture of reactive monomers. The pre-metered amount and location can be optimized to ensure that the resulting ophthalmic lens properly encapsulates the rigid insert. For example, too little MRM pre-dosing can prevent full encapsulation, and too much MRM pre-dosing can cause bubbles to form within the lens-forming cavity. In some preferred embodiments, the pre-dose amount can be approximately 10uL of MRM. Similarly, positioning the prefeed relative to the rigid insert can reduce encapsulation problems. For example, the pre-dosing position of the front bend mold can coincide with the steepest concave point of the rigid insert.
    [000105] In some embodiments, molding steps 415-445 may take place in a nitrogen rich environment, preferably with oxygen content between 0.0% and 0.5%. Consequently, the components used through the process can be balanced to the environment before use.
    [000106] In some embodiments, in 417 the stabilization features can be positioned close to the front curve template. In some embodiments, stabilization features can be positioned or deposited directly on the front curve mold. In other modalities, stabilization resources can be positioned or deposited in the pre-dosed MRM. Stabilizing features can be positioned in a defined location to allow precise alignment with the rigid insert. In other modalities, stabilization features can be added to the ophthalmic lens after the front curve mold has been fully dosed. In such embodiments, the stabilization features can be injected to a specific position to properly align with the rigid insert.
    [000107] In 420, the rigid insert can be positioned close to the face curve mold and in contact with the pre-dosed MRM, the positioning being a face curve set. In some embodiments, the rigid insert can be aligned close to the front curve mold prior to pre-dosing at 415. In such embodiments, the rigid insert can be nested in the front curve mold after the pre-dosing step at 415. In modalities where stabilization features are included with the rigid insert, the placement of the rigid insert may not require specific alignment of the front curve mold. Alternative modalities where the stabilization and rigid insert features are separately included in the ophthalmic lens may require specific alignment between the rigid insert and the front curve mold or, more specifically, the stabilization features.
    [000108] In some preferred embodiments, at 420 the rigid insert can be placed by mechanical positioning. Mechanical positioning can include, for example, a robot or other automation, such as those known in the industry to position surface mount components or an automatic pick and place apparatus. Positioning of a rigid insert by humans is also within the scope of the present invention. Consequently, mechanical positioning can be effective if it positions the rigid insert in a mold part such that polymerization of a reactive mixture contained by the mold part can include the rigid insert in a resulting ophthalmic lens.
    [000109] In some embodiments, in 425 the MRM can be pre-cured to hold the rigid insert for the remaining encapsulation process. For example, the front curve assembly can be pre-cured under a blue curing lamp at 5mW for 2 minutes at an ambient temperature such as 22 °C. Some alternative modalities can simultaneously perform multiple encapsulation steps. In such embodiments, the precure step at 425 may not be necessary.
    [000110] At 430, the front curve assembly can be post-dosed with the remaining MRM that may be needed to fully encapsulate the rigid insert and create an ophthalmic lens. At 435, the tail curve mold may be positioned close to the front curve assembly, where the positioning forms a cavity between the tail curve mold and the front curve mold. The lens forming cavity can define the shape of the ophthalmic lens, and the MRM can completely encapsulate the rigid insert within the cavity.
    [000111] In some embodiments, at 440 the front and back curve set can be pre-healed to a point that can reinforce the set. Pre-cure at 440 can prevent displacement or tilt of the front and rear bend assembly components during the full cure process. Pre-cure can be a short process occurring immediately after the full construction of the front and back curve assembly.
    [000112] In 445, the front and back curve set can be fully cured. The mixture of reactive monomers within the cavity can be polymerized. Polymerization can be carried out, for example, by exposure to one or both of actinic radiation and heat. The parameters of the curing process can be defined by the specific chemistry of the MRM and the rigid insert. For example, exposure to radiation can cure MRM, but radiation can degrade or affect rigid insert integrity. In some modalities, the cure time may be extended to allow for tolerable curing conditions.
    [000113] In 450, the front bend and back bend assembly can be unmolded. In some embodiments, at 450 the front and back bend assembly can be demolded by separating the front bend mold from the back bend mold. Some embodiments can pull the front curve mold from the assembly, others can pull the back curve mold from the assembly, and still others can pull the front curve mold and the rear curve mold. The pulled mold can define how the ophthalmic lens can be removed from the demolded assembly.
    [000114] In 455, the ophthalmic lens with the rigid lens can be removed from the demolded front and back curve assembly. After demolding, the ophthalmic lens can remain attached to either the front curve mold or the posterior curve mold. In some embodiments, the ophthalmic lens may remain in the part of the mold that is not pulled out during the mold removal process at 450.
    [000115] In some embodiments, the part of the mold that includes the ophthalmic lens may be manipulated to release the ophthalmic lens. Manipulation may include, for example, flexing the mold piece, and may allow for easier removal of the ophthalmic lens. In some embodiments, the mold part including the ophthalmic lens may be shaken. The removal process at 455 can take place while the mold part and the ophthalmic lens are submerged in a solution, eg, a temperature-controlled bath. Submerging the ophthalmic lens and mold piece in an aqueous solution can allow partial swelling of the ophthalmic lens, which can facilitate removal of the mold piece.
    [000116] In modalities where the ophthalmic lens remains in the front curve mold, removal of the ophthalmic lens may require additional steps. For example, a solution can be injected into the lens edges to lift the ophthalmic lens off the front curve mold surface.
    [000117] At 460, the ophthalmic lens can be hydrated. The hydration process at 460 may allow the ophthalmic lens to be compatible with an eye, whereby the functionality of the ophthalmic lens including the rigid insert may depend on said compatibility. In some modalities, the hydration process can comprise multiple stages to allow for proper swelling of the ophthalmic lens. For example, the first stage might include submerging the ophthalmic lens in a solution of about 0.45% sodium borate at 50 °C for one hour. The second stage can repeat the conditions of the first stage with a new solution. The third and final stage may include submerging the lens in a room temperature solution.
    [000118] In 465, the ophthalmic lens can be packaged in a sealed container. The sealed container can prevent exposure to air and can include a solution to prevent the lens from drying out before use.
    [000119] Although the invention is used to provide hard or soft contact lenses made of any ophthalmic lens material, or material suitable for the manufacture of such lenses, preferably the ophthalmic lenses of the invention are soft contact lenses having contents of water from approximately 0 to 90 percent. More preferably, ophthalmic lenses are made from monomers containing one or both of hydroxy groups and carboxyl groups, or are made from silicone-containing polymers such as siloxanes, hydrogels, silicone hydrogels, and combinations thereof. The material useful for forming the ophthalmic lenses of the invention can be made by reacting mixtures of macromers, monomers, and combinations thereof together with additives such as polymerization initiators. Suitable materials include, but are not limited to, silicone hydrogels made from silicone macromers and hydrophilic monomers. DEVICE
    [000120] Referring now to Figure 5, an embodiment 500 of an automated apparatus 510 is illustrated with one or more insert transfer interfaces 511 514 As illustrated, multiple mold parts, each with an associated insert 514, are contained in a pallet 512 and presented to a media transfer interface 511. Modalities may include a single interface individually positioning rigid inserts 514 or multiple interfaces (not shown) simultaneously positioning rigid inserts 514 in multiple mold parts, and in some embodiments, in each mold.
    [000121] Another aspect of some embodiments includes an apparatus for supporting the rigid insert 514 while the ophthalmic lens body is molded around these components. Attachment points can be fixed with polymerized material of the same type that will be formed on the ophthalmic lens body. CONCLUSION
    [000122] The present invention, as described above and further defined by the claims below, provides methods for forming lenses that encapsulate a rigid insert, wherein the rigid insert can be adjusted to correct specific astigmatism characteristics of an eye and apparatus to implement such methods, as well as ophthalmic lenses formed with the rigid inserts.
    权利要求:
    Claims (15)
    [0001]
    1. Method for forming an ophthalmic lens with a rigid insert, the method characterized by the fact that it comprises the steps of: pre-dosing the front of the curve mold with a mixture of reactive monomers; positioning the rigid insert in the monomer mixture reactives; pre-cure the reactive monomer mixture to keep the rigid insert firmly close to the front curve mold, with the pre-cure forming a front curve set; post-dosing the front curve set with the front curve mixture reactive monomers, in which the pre-dosing and post-dosing amounts are able to encapsulate the rigid insert; position the back of the curve mold close to the front curve set, where the positioning forms a curve set frontal and posterior curve; cure the mixture of reactive monomers to form the ophthalmic lens; demold the front curve and posterior curve assembly; remove the ophthalmic lens from the demolded front curve and posterior curve assembly; ehydrate the ophthalmic lens.
    [0002]
    2. Method according to claim 1, characterized in that the surface of the rigid insert comprises an adhesion promoting layer.
    [0003]
    3. Method according to claim 1 or claim 2, characterized in that it further comprises the steps of: degassing at least one of: the rigid insert, the reactive monomer mixture, the front curve mold and the posterior curve, with degassing removing gases capable of creating lens defects.
    [0004]
    4. Method, according to any one of the preceding claims, characterized in that it further comprises the steps of: pre-curing the mixture of reactive monomers to fixedly maintain the posterior curve mold close to the front curve assembly.
    [0005]
    5. Method according to any one of the preceding claims, characterized in that the steps to form the front curve assembly are performed by an automated device.
    [0006]
    6. Method according to any one of the preceding claims, characterized in that the mixture of polymerized reactive monomers comprises a hydrogel and preferably, in which the hydrogel comprises a silicone hydrogel.
    [0007]
    7. Method according to any one of the preceding claims, characterized in that a plurality of ophthalmic lenses with rigid inserts is formed simultaneously on a pallet.
    [0008]
    8. Method according to any one of the preceding claims, characterized in that the rigid insert is able to correct the astigmatic vision.
    [0009]
    9. Method according to any one of the preceding claims, characterized in that the rigid insert comprises a thermoformed material.
    [0010]
    10. Method according to any of the preceding claims, characterized in that it further comprises: adding a stabilization feature to the mixture of reactive monomers, the stabilization feature being able to guide the ophthalmic lens in an eye .align the stabilization feature with the rigid insert, the alignment enabling correction of astigmatic vision when the ophthalmic lens is oriented in the eye.
    [0011]
    11. Method according to claim 10, characterized in that the rigid insert includes the stabilization feature.
    [0012]
    12. Method according to any of the preceding claims, characterized in that hydration further comprises the steps of the method of: submerging the ophthalmic lens in a solution comprising 0.45% sodium borate for at least one hour at a temperature around 50°C.
    [0013]
    13. Method according to claim 10 or 11, characterized by the fact that the stabilization resource is an injectable material that comprises an expandable index different from that of the mixture of reactive monomers.
    [0014]
    14. Method, according to claim 10 or 11, characterized by the fact that the addition of the stabilization feature: alters the surface of the front curve of the ophthalmic lens; or add mass to the ophthalmic lens, where the mass is sufficient to orient the ophthalmic lens in the eye.
    [0015]
    15. Method according to claim 10 or 11, characterized in that the stabilization feature comprises an indication of visual guidance, wherein the indication of visual guidance comprises a visible coloring or marking.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR102014006311B1|2021-08-03|METHOD FOR FORMING AN OPHTHALMIC LENS WITH A RIGID INSERT
    AU2014265100B2|2018-11-29|Method of manufacturing hydrogel ophthalmic devices with electronic elements
    TWI587031B|2017-06-11|Method and apparatus for encapsulating a rigid insert in a contact lens for correcting vision in astigmatic patients
    JP2018173645A|2018-11-08|Sealing and encapsulation in energized ophthalmic devices with annular insert
    BR102014006363A2|2014-11-18|Ophthalmic devices with stabilization resources
    BRPI0919108A2|2019-09-03|method and apparatus for forming a variable focus ophthalmic device
    TWI631384B|2018-08-01|Ophthalmic devices with stabilization features
    同族专利:
    公开号 | 公开日
    EP2778764B1|2019-11-20|
    CN104044286B|2018-01-05|
    HK1202164A1|2015-09-18|
    AU2014201552B2|2017-12-21|
    US9581832B2|2017-02-28|
    SG10201400602PA|2014-10-30|
    IL231365D0|2014-08-31|
    EP2778764A1|2014-09-17|
    TWI609775B|2018-01-01|
    KR102184890B1|2020-12-01|
    CN104044286A|2014-09-17|
    CA2846696A1|2014-09-15|
    KR20140113535A|2014-09-24|
    CA2846696C|2021-01-26|
    TW201501916A|2015-01-16|
    JP6425902B2|2018-11-21|
    IL231365A|2019-07-31|
    US20140268020A1|2014-09-18|
    AU2014201552A1|2014-10-02|
    JP2014182393A|2014-09-29|
    RU2014109968A|2015-09-20|
    BR102014006311A2|2014-12-23|
    RU2639785C2|2017-12-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4166255A|1976-06-14|1979-08-28|Minnesota Mining And Manufacturing Company|Hybrid corneal contact lens|
    US5690865A|1995-03-31|1997-11-25|Johnson & Johnson Vision Products, Inc.|Mold material with additives|
    US5849209A|1995-03-31|1998-12-15|Johnson & Johnson Vision Products, Inc.|Mold material made with additives|
    KR100445740B1|1996-12-20|2004-08-25|바슈 앤드 롬 인코포레이티드|Toric contact lens markings|
    JPH11174388A|1997-12-12|1999-07-02|Hoya Health Care Kk|Toric contact lens|
    US6217171B1|1998-05-26|2001-04-17|Novartis Ag|Composite ophthamic lens|
    WO2004015460A2|2002-08-09|2004-02-19|E-Vision, Llc|Electro-active contact lens system|
    US6250757B1|1999-12-15|2001-06-26|Johnson & Johnson Vision Products, Inc.|Hybrid refractive birefringent multifocal ophthalmic lenses|
    JP2002006269A|2000-06-22|2002-01-09|Kuraray Co Ltd|Resin mold for manufacturing contact lens and method for manufacturing contact lens|
    BR0215812A|2002-07-19|2005-04-26|Johnson & Johnson Vision Care|Rotationally stabilized contact lenses|
    EP2508936B1|2002-08-06|2016-11-23|Novartis AG|Contact lenses|
    US20040141150A1|2003-01-21|2004-07-22|Roffman Jeffrey H.|Hybrid multifocal contact lenses|
    KR20050032574A|2005-01-18|2005-04-07|존슨 앤드 존슨 비젼 케어, 인코포레이티드|Rotationally stabilized contact lenses|
    JP5154231B2|2005-02-14|2013-02-27|ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド|Comfortable ophthalmic device and its manufacturing method|
    US7625197B2|2005-09-12|2009-12-01|Johnson & Johnson Vision Care, Inc.|Devices and processes for performing degassing operations|
    US20070284770A1|2006-06-07|2007-12-13|Ansell Scott F|Decreased lens delamination during ophthalmic lens manufacture|
    US7960465B2|2006-06-30|2011-06-14|Johnson & Johnson Vision Care, Inc.|Antimicrobial lenses, processes to prepare them and methods of their use|
    US7883207B2|2007-12-14|2011-02-08|Pixeloptics, Inc.|Refractive-diffractive multifocal lens|
    KR20100015400A|2007-04-06|2010-02-12|존슨 앤드 존슨 비젼 케어, 인코포레이티드|Methods of degassing ophthalmic lens monomer mixtures|
    US20080290535A1|2007-05-24|2008-11-27|Molock Jr Frank F|Reduction of excess polymeric flash ring|
    US8262952B2|2007-10-31|2012-09-11|Bausch & Lomb Incorporated|Molds for production of ophthalmic devices|
    US20090218705A1|2008-02-28|2009-09-03|Patterson Leah K|Methods and systems for processing silicone hydrogel ophthalmic lenses for improved lens transfer|
    US7931832B2|2008-03-31|2011-04-26|Johnson & Johnson Vision Care, Inc.|Ophthalmic lens media insert|
    US8922898B2|2008-09-04|2014-12-30|Innovega Inc.|Molded lens with nanofilaments and related methods|
    US9296158B2|2008-09-22|2016-03-29|Johnson & Johnson Vision Care, Inc.|Binder of energized components in an ophthalmic lens|
    WO2011075112A1|2009-12-14|2011-06-23|Essilor International |Process for producing a curved substrate covered with a film|
    US9889615B2|2011-03-18|2018-02-13|Johnson & Johnson Vision Care, Inc.|Stacked integrated component media insert for an ophthalmic device|
    US8814350B2|2012-02-13|2014-08-26|Johnson & Johnson Vision Care, Inc.|Dynamic stabilization zones for contact lenses|US9475709B2|2010-08-25|2016-10-25|Lockheed Martin Corporation|Perforated graphene deionization or desalination|
    US10653824B2|2012-05-25|2020-05-19|Lockheed Martin Corporation|Two-dimensional materials and uses thereof|
    TW201504140A|2013-03-12|2015-02-01|Lockheed Corp|Method for forming perforated graphene with uniform aperture size|
    US9572918B2|2013-06-21|2017-02-21|Lockheed Martin Corporation|Graphene-based filter for isolating a substance from blood|
    US9731437B2|2013-11-22|2017-08-15|Johnson & Johnson Vision Care, Inc.|Method of manufacturing hydrogel ophthalmic devices with electronic elements|
    CN105940479A|2014-01-31|2016-09-14|洛克希德马丁公司|Methods for perforating two-dimensional materials using a broad ion field|
    EP3099645A4|2014-01-31|2017-09-27|Lockheed Martin Corporation|Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer|
    US9744617B2|2014-01-31|2017-08-29|Lockheed Martin Corporation|Methods for perforating multi-layer graphene through ion bombardment|
    US9834809B2|2014-02-28|2017-12-05|Lockheed Martin Corporation|Syringe for obtaining nano-sized materials for selective assays and related methods of use|
    EP3116625A4|2014-03-12|2017-12-20|Lockheed Martin Corporation|Separation membranes formed from perforated graphene|
    US9610546B2|2014-03-12|2017-04-04|Lockheed Martin Corporation|Separation membranes formed from perforated graphene and methods for use thereof|
    SG11201701654UA|2014-09-02|2017-04-27|Lockheed Corp|Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same|
    JP5873584B1|2015-03-12|2016-03-01|株式会社ホプニック研究所|Plastic lens manufacturing method, film positioning method|
    CA2994549A1|2015-08-05|2017-02-09|Lockheed Martin Corporation|Perforatable sheets of graphene-based material|
    JP2018530499A|2015-08-06|2018-10-18|ロッキード・マーチン・コーポレーション|Nanoparticle modification and perforation of graphene|
    WO2017180141A1|2016-04-14|2017-10-19|Lockheed Martin Corporation|Selective interfacial mitigation of graphene defects|
    US10980919B2|2016-04-14|2021-04-20|Lockheed Martin Corporation|Methods for in vivo and in vitro use of graphene and other two-dimensional materials|
    JP2019519756A|2016-04-14|2019-07-11|ロッキード・マーチン・コーポレーション|In-situ monitoring and control of defect formation or defect repair|
    JP2019517909A|2016-04-14|2019-06-27|ロッキード・マーチン・コーポレーション|Two-dimensional membrane structure having a flow path|
    CA3020686A1|2016-04-14|2017-10-19|Lockheed Martin Corporation|Method for treating graphene sheets for large-scale transfer using free-float method|
    WO2017180135A1|2016-04-14|2017-10-19|Lockheed Martin Corporation|Membranes with tunable selectivity|
    KR101943288B1|2016-04-20|2019-01-28|쿠퍼비젼 인터내셔날 홀딩 캄파니, 엘피|Silicone elastomer - silicone hydrogel hybrid contact lens|
    US10139521B2|2016-04-20|2018-11-27|Coopervision International Holding Company, Lp|Silicone elastomer-hydrogel hybrid contact lenses|
    TWI718469B|2019-01-09|2021-02-11|優你康光學股份有限公司|Mould and method for demolding contact lens|
    CN111483099A|2019-01-25|2020-08-04|优你康光学股份有限公司|Mold for demolding contact lenses and method thereof|
    法律状态:
    2014-12-23| B03A| Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]|
    2015-03-03| B03H| Publication of an application: rectification [chapter 3.8 patent gazette]|Free format text: REFERENTE A RPI 2294 23/12/2014, QUANTO AO ITEM (54). |
    2018-11-13| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-03-31| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-05-18| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-08-03| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    US13/833,553|2013-03-15|
    US13/833,553|US9581832B2|2013-03-15|2013-03-15|Method and apparatus for encapsulating a rigid insert in a contact lens for correcting vision in astigmatic patients|
    [返回顶部]